Keywords: laxoSmithKline, R&D, Rare diseases, Prosensa, JCR, Management

GSK launches new specialist rare diseases R&D unit; names new president for GSK Japan

Article | 5 February 2010

UK drugs giant GlaxoSmithKline revealed yesterday that it has formed a new standalone unit specializing in the development and commercialization of medicines for rare diseases and has recruited a new head for its Japanese business.

Over 5,500 rare diseases have been identified of which less than 10% are currently being treated, presenting a significant unmet medical need, noted GSK. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in